CXCR4 and Miyoshi myopathy: At our institution, the novel CXCR4-directed endoradiotherapy (ERT) has shown promising efficacy (ORR 75%) but no favorable survival outcome (median PFS 54 days, range 13–175 days and median OS 223 days, range 13–313 days) in extramedullary relapsed MM [42].